Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials
In this NMA, tirzepatide 10 and 15 mg were associated with improved efficacy versus liraglutide, improved or comparable efficacy versus semaglutide, and all interventions had a generally comparable safety profile for achieving weight reduction and reducing cardiometabolic risk factors among patients with obesity or overweight.
Authors
- Erin Johansson (ORCID: https://orcid.org/0009-0006-3178-1622)
- Tristan Curteis
- Sarah Zimner-Rapuch
- Manon Rubinstein
- Laura J. Clark
- Helene Sapin
- Georgios K. Dimitriadis
- Ludi Fan
- Andreea Ciudin
Institutions
- Hebron University (PS)
- Eli Lilly (United States) (US)
- Vall d'Hebron Hospital Universitari (ES)
- Costello Medical Consulting (United Kingdom) (GB)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s12325-026-03523-5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company